featured
Pirfenidone in Patients With Progressive Fibrotic ILDs Other Than Idiopathic Pulmonary Fibrosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pirfenidone in Patients With Progressive Fibrotic Interstitial Lung Diseases Other Than Idiopathic Pulmonary Fibrosis (RELIEF): A Double-Blind, Randomised, Placebo-Controlled, Phase 2b Trial
Lancet Respir Med 2021 Mar 30;[EPub Ahead of Print], J Behr, A Prasse, M Kreuter, J Johow, KF Rabe, F Bonella, R Bonnet, C Grohe, M Held, H Wilkens, P Hammerl, D Koschel, S Blaas, H Wirtz, JH Ficker, W Neumeister, N Schönfeld, M Claussen, N Kneidinger, M Frankenberger, S Hummler, N Kahn, S Tello, J Freise, T Welte, P Neuser, A GüntherFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.